{"filings":[{"id":1196399,"accession_number":"0001493152-26-029607","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-06-22T20:45:20+00:00","items":[],"status":"ready","headline":"Genelux stockholders re-elect John Smither as Class I director, ratify Weinberg & Co. as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Smither re-elected as Class I director: 8,696,891 for, 3,393,408 withheld, 16,172,901 broker non-votes.","Ratification of Weinberg & Company as independent auditor for FY 2026: 28,092,768 for, 105,158 against, 65,274 abstain.","Annual meeting held June 16, 2026; 63.03% of 44,842,243 outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102089,"accession_number":"0001493152-26-011649","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Genelux enters $100M at-the-market equity offering agreement with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement with TD Cowen allows offering of common stock up to $100M aggregate.","TD Cowen receives up to 3.0% commission on gross proceeds from sales.","Proceeds for general corporate purposes, including R&D, clinical trials, and capex.","Company has no obligation to sell shares; may suspend at any time.","Shares offered via at-the-market program on Nasdaq or negotiated transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102088,"accession_number":"0001493152-26-004755","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux furnishes updated corporate presentation; no specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated February 2026 includes business and strategic updates.","No quantitative data, financial results, or material events specified in the filing or available exhibit.","Document furnished under Regulation FD and posted on investor relations website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102087,"accession_number":"0001493152-26-000989","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genelux prices $20M public offering of 6.7M shares at $3.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced underwritten public offering of 6,666,667 shares at $3.00 each.","Gross proceeds of approx. $20M before underwriting discounts and expenses.","Underwriter granted 30-day option to buy up to 1,000,000 additional shares.","Proceeds for general corporate purposes including R&D, clinical trials, and working capital.","Offering expected to close January 9, 2026; sole book-runner Lucid Capital Markets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102086,"accession_number":"0001493152-26-000270","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.","NSCLC Phase 2 VIRO-25: 60% DCR (3/5 patients); tumor size changes -18.9% and -22.7% in two of three DCR patients.","Durability signals: two SCLC PR patients had PFS of 12.1 mo (1 prior line) and 7.7 mo (4 prior lines).","Topline Phase 3 ovarian cancer data expected H2 2026; additional lung cancer interim readouts throughout 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102085,"accession_number":"0001493152-26-000115","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Genelux appoints Jason Litten as CMO after Paul Scigalla resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Scigalla, M.D., resigned as CMO effective December 30, 2025.","Jason Litten, M.D., appointed CMO effective January 2, 2026; previously CMO at Chimeric Therapeutics.","Dr. Litten receives base salary of $475,000/year, 40% target bonus, and option to purchase 275,000 shares vesting over 4 years.","Severance: 6 months salary (non-CIC) or 12 months (CIC) plus COBRA coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134857,"accession_number":"0001641172-25-026390","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Genelux reprices employee stock options to $3.33 from up to $22.40; covers 2.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercise price reduced to $3.33 for eligible options with prior range $6.00–$22.40 per share.","Repricing covers approximately 2,715,583 shares under 2009/2019/2022 equity plans; exec holdings included.","CEO Thomas Zindrick holds 1,355,940 repriced options; other officers listed with 8,333–272,652 shares.","No changes for non-employee directors or 2023 inducement plan options; original vesting and expiry unchanged.","2025 annual meeting: Zindrick and Tyree re-elected as Class III directors; Weinberg & Company ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170657,"accession_number":"0001641172-25-000642","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Genelux prices $10.5M underwritten offering of 3M shares at $3.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $10.5M from 3,000,000 shares at $3.50 per share; closing expected March 26, 2025.","Underwriter receives warrant to purchase 120,000 shares at $4.20 per share, exercisable after 180 days.","Proceeds for working capital and continued clinical development of Olvi-Vec.","Titan Partners Group acting as sole bookrunner; offering under effective shelf registration S-3.","Shares sold in registered direct offering; underwriting discounts and expenses not yet disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170656,"accession_number":"0001641172-25-000528","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Genelux reports preliminary cash ~$30.9M; positive Olvi-Vec SCLC data and FDA guidance for PRROC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and short-term investments as of Dec 31, 2024: ~$30.9M (unaudited).","Phase 1b/2 SCLC data: 71% disease control rate among 7 evaluable patients; 2 partial responses; 79% tumor reduction in one.","FDA Type D meeting for Olvi-Vec in PRROC: FDA indicated clinically meaningful PFS advantage without OS decrement could support traditional approval; pre-BLA meeting recommended.","Anticipates reporting Phase 3 topline (OnPrime/GOG-3076) in H1 2026 and Phase 2 VIRO-25 interim in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170655,"accession_number":"0001493152-25-004554","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Genelux CFO Lourie Zak resigns; Matt Pulisic appointed CFO with $410k salary, 275k option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lourie Zak resigned as CFO effective Jan 29, 2025; separation includes $180k cash payment (6 months salary) and advisory role through Aug 29, 2025.","Matt Pulisic appointed CFO effective Jan 30, 2025; previously VP Finance at Arrowhead Pharmaceuticals.","Pulisic receives base salary of $410,000/year, target bonus of 40% of base, and option to purchase 275,000 shares at $3.95/share.","Option vests over 4 years (25% after one year, then monthly); full acceleration upon change in control.","Pulisic eligible for severance: 6 months base salary without cause, 12 months base salary if termination within change in control period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187635,"accession_number":"0001493152-24-044258","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux furnishes corporate presentation on November 8, 2024; no specific financial or operational updates available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Genelux made available a corporate presentation for use in investor and analyst meetings.","No financial results, guidance, or material events were announced in the filing.","The presentation includes forward-looking statements with accompanying cautionary language."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187634,"accession_number":"0001493152-24-039417","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Genelux VP of Quality Caroline Jewett resigns effective Oct 18, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Caroline Jewett resigned as VP, Head of Quality, effective October 18, 2024.","No successor or interim replacement has been announced.","Departure is a voluntary resignation; no reason disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204118,"accession_number":"0001493152-24-030410","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Genelux holds 2024 annual meeting; elects two Class II directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Mary Mirabelli as Class II director with 13,349,192 votes for, 1,386,089 withheld, and 7,740,438 broker non-votes.","Elected John Thomas, Ph.D. as Class II director with 9,417,742 votes for, 5,317,539 withheld, and 7,740,438 broker non-votes.","Ratified Weinberg & Company as independent auditor for FY 2024: 20,271,624 for, 99,110 against, 2,104,985 abstentions.","Quorum of 22,475,719 shares (65.43% of outstanding) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204117,"accession_number":"0001493152-24-029876","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux posts corporate presentation on August 1, 2024; no specific new data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Furnished corporate presentation as Exhibit 99.1 under Regulation FD.","Presentation may be used by management in future meetings; no financial results or guidance provided.","Presentation content not included in this filing; summary cannot be produced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220842,"accession_number":"0001493152-24-022621","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Genelux receives ~$2.35M net from partial overallotment exercise by underwriters","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised option to purchase 625,000 shares and warrants at $4.00 per unit.","Net proceeds after discounts and expenses were approximately $2.35 million.","Warrants have $5.25 exercise price and include a 9.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220841,"accession_number":"0001493152-24-021265","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Genelux prices $27.5M offering of 6.875M shares and warrants at $4.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$27.5M; net ~$25.4M from 6,875,000 shares and 6,875,000 warrants at combined $4.00/unit.","Each warrant exercisable at $5.25, immediately exercisable, expires 5 years from issuance.","Underwriters granted 30-day option for additional 1,031,250 shares and warrants (15% over-allotment).","Proceeds to fund working capital into Q1 2026 and Olvi-Vec development; Phase 3 OnPrime topline expected H2 2025.","Closing expected May 29, 2024; Guggenheim Securities sole bookrunner, Newbridge Securities co-manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220840,"accession_number":"0001493152-24-014071","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux files corporate presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated April 9, 2024 covers company overview and strategy.","No revenue, earnings, or guidance figures were included in the filing.","Investors should review the full presentation for any material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220839,"accession_number":"0001493152-24-012563","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux makes corporate presentation available; no material updates in text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a corporate presentation under Regulation FD on April 1, 2024.","Presentation content not detailed in filing; no specific financial or operational figures provided.","No earnings, M&A, leadership changes, or other material events disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240439,"accession_number":"0001493152-24-004898","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux provides corporate presentation; content not summarized in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation made available on February 5, 2024, for investor meetings.","Filing does not excerpt presentation details; no financial or operational data disclosed.","Materiality of any new information cannot be assessed from the 8-K text alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240438,"accession_number":"0001493152-24-004778","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Genelux estimates Dec 31, 2023 cash at ~$23.2M, preliminary and unaudited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and short-term investments estimated at approximately $23.2 million as of December 31, 2023.","Preliminary estimate, subject to change upon completion of quarter-end and year-end financial close processes.","Estimate has not been audited or reviewed by independent registered public accounting firm; no opinion expressed.","Company has not yet completed financial statement closing procedures; additional disclosure required for full picture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257958,"accession_number":"0001493152-23-044487","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux posts corporate slide presentation; no specific news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company issued a corporate slide presentation on December 12, 2023 via Item 7.01.","Presentation content is not included in the filing; no financial or operational details provided.","Management may use the slides in future meetings; forward-looking statements disclaimer applies.","No material business updates, guidance, or transactions were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257957,"accession_number":"0001493152-23-042634","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Genelux VP of Finance Doug Samuelson resigns effective Nov 21, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Doug Samuelson resigned as VP, Finance, effective immediately on November 21, 2023.","No replacement or interim appointment was announced in the filing.","Reason for resignation was not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257956,"accession_number":"0001493152-23-036730","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Genelux files 8-K with corporate presentation; no material new details provided","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation made available as Exhibit 99.1 but content not disclosed in filing body.","No specific financial results, guidance changes, or operational updates identified.","Presentation may be used for investor meetings; caution regarding forward-looking statements noted.","Filing is under Regulation FD and does not constitute incorporation by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275280,"accession_number":"0001493152-23-032543","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Genelux adopts 2023 Inducement Plan reserving 1M shares; John Smither elected director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 2023 Inducement Plan reserving 1,000,000 shares for new-hire equity awards as inducement material under Nasdaq Listing Rule 5635(c)(4).","Forms of stock option and restricted stock unit agreements adopted for executive officers and lower-level employees.","At Sept 11 annual meeting, John Smither elected Class I director with 15,084,240 votes for; 1,748,277 broker non-votes.","Ratification of Weinberg & Company as independent auditor passed with 16,829,075 votes for, 689 against.","Plan is substantially similar to the existing stockholder-approved 2022 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275279,"accession_number":"0001493152-23-030295","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Genelux appoints Lourie Zak as CFO effective August 28, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lourie Zak named CFO, principal financial officer, and principal accounting officer.","Zak receives $360,000 base salary, bonus target of 40%, and option for 150,000 shares vesting over 4 years.","Thomas Zindrick (CEO) and Doug Samuelson (former CFO) relinquish principal financial and accounting officer roles.","Samuelson continues as VP, Finance under prior offer letter; no family relationships or other arrangements disclosed.","Separately, Zak eligible for severance of 12 months' salary plus bonus upon qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275278,"accession_number":"0001493152-23-024868","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Genelux: Olvi-Vec estimated billion+ US market; interim data in recurrent NSCLC expected mid-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Olvi-Vec estimated to represent more than $1 billion annual US market opportunity.","Interim data from systemic Olvi-Vec trials in recurrent NSCLC expected as early as mid-2024.","Corporate presentation outlines pipeline and commercial potential for lead candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275277,"accession_number":"0001493152-23-024590","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Director Gabe Woodward resigns; Genelux audit committee size fails Nasdaq rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Gabe Woodward resigned from the Board effective July 12, 2023, at request of his partnership after IPO completion.","Resignation reduced audit committee to two independent directors, violating Nasdaq Rule 5605(c)(2)(A) requiring three.","Company notified Nasdaq on July 12, 2023; intends to rely on cure provision in Rule 5605(c)(4)(B).","Woodward's departure was not due to any disagreement with the company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292740,"accession_number":"0001493152-23-022627","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Genelux provides Phase 3 enrollment timeline for Olvi-Vec and cash runway into Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment for Phase 3 trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer expected to complete mid-2024 with 11-month follow-up.","Initial interim data for Phase 2 trial of Olvi-Vec in recurrent non-small-cell lung cancer expected as early as mid-2024.","Cash operating runway expected to extend into first quarter of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292739,"accession_number":"0001493152-23-020828","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Genelux Corp raises ~$18M in private placement of 900K shares at $20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$18M from sale of 900K shares of common stock at $20 per share.","One investor committed to fund up to $12.5M after initial closing by Nov 15, 2023.","Initial closing expected on or before June 20, 2023, subject to customary conditions.","Company to file registration statement for resale of shares within 30 days after initial closing.","Securities offered in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292738,"accession_number":"0001493152-23-019861","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Genelux formalizes CEO Thomas Zindrick employment agreement with $595K salary, bonus, and severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary set at $595,000 per year effective April 1, 2023.","Eligible for annual discretionary bonus up to 55% of base salary.","Equity awards vest 25% on first anniversary, then monthly over 36 months.","Severance: 12 months salary plus target bonus outside change in control; 18 months plus bonus within CIC period.","COBRA premiums paid for up to 12 or 18 months depending on termination timing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313382,"accession_number":"0001193125-23-019058","cik":1231457,"company_name":"GENELUX Corp","ticker":"GNLX","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["5.02","5.03","8.01","9.01"],"status":"ready","headline":"Genelux closes $15M IPO at $6.00/share; reprices stock options to IPO price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 2,500,000 shares at $6.00/share closed Jan 30, 2023; gross proceeds ~$15M.","Underwriters granted five-year warrants for 175,000 shares at $6.00/share; option for 375,000 more.","Stock option repricing: 4,037,386 options with original exercise prices $9.00-$10.50 repriced to $6.00.","Executive officers and directors hold 2,730,568 of the repriced shares.","Amended and restated certificate of incorporation and bylaws adopted effective with IPO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":139453690.75163397,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}